GET DAILY SIGNALSTvardi Therapeutics (TVRD) Q3 2026 Earnings: Pipeline Progress and Cash Runway Insights
Key Takeaways
- Tvardi Therapeutics is expected to report its third quarter (Q3) 2026 results in mid-November 2026, covering the period ended September 30, 2026.
- Analysts project a net loss of roughly $0.51 to $0.57 per share for Q3 2026, an improvement from the $0.59 loss reported in the same quarter a year earlier.
- As a clinical-stage biopharmaceutical company, Tvardi is expected to report essentially $0 in revenue, so attention will center on operating expenses and cash position.
- Recent catalysts, including positive Phase 1 data for TTI-109 and the selection of ulcerative colitis as its first indication, may shape management commentary.
- In its prior report, Tvardi posted a loss of $0.69 per share, wider than the consensus estimate, underscoring how closely investors watch its spending trajectory.
- For additional context, visit Tickeron's pages for Major News, Today's Price Move, Price Targets, and Forecast.
- Explore Trending AI Robots to discover AI-driven trading strategies and market insights.
Putting the Earnings Report in Context
Tvardi Therapeutics (TVRD) focuses on oral small-molecule therapies targeting STAT3, a protein linked to inflammatory and proliferative conditions. As a clinical-stage firm without product revenue, its quarterly updates highlight research spending efficiency, balance sheet strength, and remaining cash runway rather than top-line sales. With TTI-101 and TTI-109 moving through trials, the Q3 2026 release should offer a useful snapshot of near-term catalysts and financial sustainability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Expect for Q3 2026
Consensus estimates call for a net loss between about $0.51 and $0.57 per share in the third quarter of 2026, with revenue expected at or near zero. That would mark a modest improvement from the $0.59 per-share loss in Q3 2025. The most recent quarter, Q2 2026, showed a wider $0.69 loss that exceeded estimates, so investors will look for signs of tighter control over expenses. Beyond earnings per share, the report will likely detail research and development outlays, general and administrative costs, and quarter-end cash, cash equivalents, and marketable securities.
Investor Sentiment and Potential Market Reaction
Heading into the report, sentiment around TVRD reflects the usual swings seen in clinical-stage biotech names. Shares have moved sharply over the past year, yet analysts largely hold a Buy rating with a broad range of price targets. Much of the positive view traces to July 2026 Phase 1 data on TTI-109 that validated the drug’s mechanism and showed reductions in relevant immune cell populations. Still, risks remain, including the earlier Phase 2 miss for TTI-101 in idiopathic pulmonary fibrosis. Because revenue is not a factor, any stock reaction will probably hinge on cash-burn trends, runway updates, and clinical commentary.
Key Factors to Follow Going Forward
Attention should stay on Tvardi’s cash position and the status of its two lead programs. In October 2026 the company chose ulcerative colitis as the first indication for TTI-109, with a trial slated for 2027; updates on timelines or additional indications will be noteworthy. Spending discipline matters as well, since rising research costs could shorten the runway and raise the prospect of future financing. Management comments on cash sufficiency and operating expenses for the rest of 2026 and into 2027 will be closely watched. Broader developments around TTI-101, including further review of the Phase 2 idiopathic pulmonary fibrosis data, could also influence next steps for the pipeline.
Refining Biotech Research with AI Tools
I’ve found Tickeron’s AI Screener helpful for monitoring clinical-stage names like this one. It lets users filter thousands of stocks and ETFs by technical patterns, fundamentals, trends, volatility, and AI signals, making it easier to spot sector momentum and compare opportunities without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TVRD in upward trend: price rose above 50-day moving average on November 09, 2026
TVRD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TVRD as a result. In 67 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TVRD just turned positive on October 15, 2026. Looking at past instances where TVRD's MACD turned positive, the stock continued to rise in 29 of 37 cases over the following month. The odds of a continued upward trend are 78%.
Following a +64.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVRD advanced for three days, in 185 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TVRD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TVRD entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (3.498). P/E Ratio (-0.334) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. TVRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TVRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement